Gamma butirolactona

Descripción Del Producto

1. Classification and Chemical Overview

Gamma-butyrolactone (commonly abbreviated as GBL; systematically designated as oxolan-2-one or dihydrofuran-2(3H)-one) is a hygroscopic, colorless, oily liquid with a faint, characteristic sweet-to-caramel or industrial solvent-like odor. Chemically, it is a cyclic aliphatic ester (a 5-membered lactone) derived from 4-hydroxybutanoic acid. It possesses an empirical molecular formula of $\text{C}_4\text{H}_6\text{O}_2$, a molecular weight of $86.09\text{ g/mol}$, a density of $1.12\text{ g/cm}^3$, and is fully miscible with water, ethanol, and most organic solvents.

In commercial and industrial chemistry, GBL is widely synthesized and utilized as an industrial polar aprotic solvent, paint stripper, circuit board cleaner, and chemical precursor in the industrial synthesis of polymers (such as polybutyrolactone) and pyrrolidone derivatives. In biological systems and clinical pharmacology, however, GBL functions as an uninhibited, rapid-onset prodrug of gamma-hydroxybutyric acid (GHB).

Within the United Kingdom regulatory framework, GBL possesses no marketing authorisation (MA) from the Medicines and Healthcare products Regulatory Agency (MHRA) for human consumption. It is not catalogued in the British National Formulary (BNF) and holds no therapeutic status as a Prescription Only Medicine (POM), Pharmacy (P) medicine, or General Sales List (GSL) drug under the Human Medicines Regulations 2012. (While pharmaceutical sodium oxybate—the sodium salt of GHB—is licensed as a POM under the proprietary brand Xyrem for refractory narcolepsy with cataplexy, GBL itself is never used therapeutically).

Under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001, GBL is scheduled as a Class B controlled drug. Originally brought under Class C control in December 2009 following formal recommendations from the Advisory Council on the Misuse of Drugs (ACMD), the UK Home Office reclassified GBL (alongside 1,4-butanediol [1,4-BD]) to Clase B in April 2022 to reflect its severe addiction potential, prominent role in drug-facilitated sexual assault, and high mortality rate. Under the Control of Poisons and Explosives Precursors Regulations, legitimate industrial users and businesses require a Home Office Controlled Drug licence or registration to possess, manufacture, import, or distribute GBL. Unlicensed personal possession, importation, or supply carries severe criminal penalties.

2. Mechanism of Action and Pharmacodynamics

The pharmacodynamic profile of GBL is governed almost entirely by its quantitative, near-instantaneous in vivo conversion to gamma-hydroxybutyrate (GHB), exerting profound, concentration-dependent biphasic actions on the central nervous system:

• Enzymatic Bioactivation to GHB: GBL possesses negligible direct affinity for central neurotransmitter receptors in its intact cyclic lactone form. Upon entering the vascular compartment, systemic and hepatic lactonases (predominantly paraoxonase-1 [PON1] and serum carboxyl esterases) rapidly hydrolyze the lactone ring, cleaving it into free gamma-hydroxybutyric acid (GHB).

• Biphasic Neuroreceptor Pharmacology:

  • Low-Dose / Initial GHB Receptor Stimulation: At low circulating concentrations, GHB binds with high nanomolar affinity ($K_i \approx 30\text{ to }100\text{ nM}$) to specific, high-affinity presynaptic and postsynaptic GHB receptors (G-protein-coupled receptors distributed densely in the cortex, hippocampus, and amygdala). Stimulation of these receptors modulates intracellular signaling and promotes the presynaptic synthesis and transient release of dopamine, producing early subjective alertness, pro-sociality, mild euphoria, and motor restlessness.

  • High-Dose / Overriding $GABA_B$ Receptor Agonism: As concentrations rise into the micromolar range (such as with recreational or repeated dosing), GHB binds as a direct partial agonist at the central $GABA_B$ receptor complex ($EC_{50} \approx 100\text{ to }500\text{ \mu M}$). The $GABA_B$ receptor is an obligate heterodimer ($GABA_{B1}/GABA_{B2}$) coupled to inhibitory $G_{\alpha i/o}$ proteins. Its activation suppresses adenylyl cyclase, lowers intracellular cAMP, blocks presynaptic N- and P/Q-type voltage-gated calcium channels, and opens postsynaptic G-protein-coupled inwardly rectifying potassium (GIRK) channels. This triggers massive, generalized neuronal hyperpolarization, arrests striatal dopaminergic and thalamocortical firing, and produces profound central nervous system depression, loss of consciousness (“G-sleep” / “G-hole”), muscle hypotonia, and central hypoventilation.

• Paradoxical Dopaminergic Rebound: Because high concentrations of GHB via $GABA_B$ activation profoundly suppress dopaminergic neurotransmission, intracellular stores of dopamine accumulate within presynaptic vesicles in the striatum. When GHB concentrations decline below the $GABA_B$ threshold (typically 2 to 4 hours post-ingestion), the inhibition is suddenly removed, while low-dose GHB receptor stimulation persists. This triggers an abrupt, massive release of accumulated dopamine, manifesting clinically as sudden, unprovoked awakening from deep comatose sleep, accompanied by marked psychomotor agitation, tachycardia, diaphoresis, and tremors.

• Endocrine Effects: Systemic GHB profoundly stimulates hypothalamic growth hormone-releasing hormone (GHRH) and blunts prolactin-inhibiting pathways, producing acute, transient surges in systemic human growth hormone (hGH) secretion (a phenomenon historically exploited in bodybuilding subcultures).

3. Approved UK Clinical Indications and Therapeutic Scope

GBL possesses no approved human clinical indications in the United Kingdom. No clinical trials have ever supported the administration of unformulated GBL in human medicine due to its rapid conversion, caustic mucosal toxicity, and severe risk profile.

The National Institute for Health and Care Excellence (NICE) does not integrate GBL into any therapeutic pathway. In clinical practice, regulated pharmaceutical-grade oral sodium oxybate (Xyrem, POM) is restricted to specialist neurological prescribing for severe narcolepsy with cataplexy in adult patients refractory to standard medications.

The practical presentation of GBL is confined entirely to illicit substance misuse, recreational nightlife environments, and sexualised drug use (“chemsex”) settings (colloquially termed “G”, “liquid ecstasy”, or “cleaner”). In these non-medical contexts, it is sought for:

• Inducing rapid euphoric intoxication, emotional disinhibition, and sensory enhancement.

• Heightening sexual arousal, tactile sensation, and facilitating prolonged sexual endurance.

• Athletic/bodybuilding performance support (illicitly exploited for its purported hGH-releasing and deep slow-wave sleep-inducing properties).

• Non-consensual drug-facilitated sexual assault (DFSA) and spiked drink incidents, facilitated by its clear liquid appearance and rapid incapacitating effects when dissolved in flavored beverages.

GBL holds no status within the NHS drug tariff, cannot be prescribed on NHS prescription forms (FP10), and must never be procured or administered for human medical consumption.

4. Pharmacokinetic Profile and Metabolic Fate

The clinical hazards of GBL are critically defined by its distinct pharmacokinetic superiority over parent GHB in terms of absorption velocity, lipophilicity, and biological potency:

• Absorption: Following oral ingestion, GBL is absorbed across the gastric and upper intestinal mucosa far more rapidly than equimolar doses of pharmaceutical GHB. Because GBL is an uncharged, neutral cyclic lactone, it is substantially more lipophilic than the highly polar, ionized carboxylate salt of sodium GHB. Consequently, it readily crosses cell membranes via passive diffusion without requiring active monocarboxylate transporter (MCT) systems. Subjective and physiological onset occurs within 10 to 20 minutes (compared to 30 to 45 minutes for sodium GHB), with peak plasma concentrations ($C_{max}$) reached within 20 to 45 minutes.

• Potency Ratio vs. GHB: Due to differences in molecular weight and rapid membrane transit, GBL is significantly more potent than sodium GHB on a milligram-for-milligram (or volume-for-volume) basis:

  $$\text{1.0 mL of pure GBL (density 1.12 g/mL)} \approx \text{1.12 g GBL} \longrightarrow \text{hydrolyzed in vivo to} \approx \text{1.6 g of sodium GHB}$$

  Consequently, an accidental volumetric measuring discrepancy of as little as $0.3\text{ to }0.5\text{ mL}$ is sufficient to transition a user from functional euphoria to profound, unarousable comatose collapse.

• Distribution: Following rapid hydrolysis in the bloodstream, liberated GHB distributes widely throughout the total body water compartment, exhibiting an apparent volume of distribution ($V_d$) of approximately $0.4\text{ to }0.6\text{ L/kg}$. GHB displays negligible binding to human plasma proteins ($<1\%$) and crosses the blood-brain barrier (BBB) via both passive diffusion (enhanced when entering as intact lipophilic GBL) and active carrier-mediated transport via the monocarboxylate transporter 1 (MCT1 / SLC16A1). It readily crosses the placental barrier and distributes into breast milk.

• Biotransformation: Liberated GHB is cleared primarily through hepatic and extrahepatic oxidative metabolism via the physiological endogenous GHB/GABA catabolic cascade:

  • Oxidation to Succinic Semialdehyde: GHB is oxidized by cytosolic NADP+-dependent GHB dehydrogenase (and secondary alcohol dehydrogenases) to succinic semialdehyde (SSA).

  • Conversion to Succinate: Succinic semialdehyde dehydrogenase (SSADH) oxidizes SSA into succinate (succinic acid).

  • Kreb’s Cycle Catabolism: Succinate enters the mitochondrial citric acid (Krebs) cycle, where it is ultimately oxidized into water ($H_2O$) and carbon dioxide ($CO_2$), which is exhaled via the lungs.

  • Capacity-Limited (Non-Linear) Kinetics: At low doses, clearance is rapid. However, at typical recreational and toxic doses, the enzymatic capacity of GHB dehydrogenase and SSADH becomes saturated, shifting elimination from linear first-order to zero-order (Michaelis-Menten) kinetics. Under saturated states, small incremental increases in dose trigger disproportionate, exponential spikes in circulating serum concentrations and elimination half-life.

• Elimination: Systemic clearance of GBL/GHB is rapid, occurring almost entirely via pulmonary exhalation of metabolic $CO_2$, with less than $2\text{ to }5\%$ excreted unchanged in the urine. The apparent terminal elimination half-life ($t_{1/2}$) of converted GHB in humans is exceptionally short, averaging 30 to 50 minutes at low doses, extending to 60 to 90 minutes in overdose. Due to this ultra-short half-life, the substance is cleared from circulating blood within 4 to 8 hours and becomes undetectable in standard forensic urine specimens within 10 to 12 hours post-ingestion, posing severe challenges for clinical toxicology and forensic DFSA investigations.

5. Physiological Effects and Adverse Event Spectrum

The clinical presentation of GBL consumption is characterized by a steep, unpredictable dose-response curve where therapeutic/recreational effects rapidly collapse into life-threatening toxicity:

• Acute Central Nervous System Depression and Coma (Very Common, $\ge 1/10$):

  • Sudden Comatose Collapse (“G-Out”): Rapid onset of unarousable stupor or Glasgow Coma Scale (GCS) score drop to $3$, typically occurring within 20 to 45 minutes of ingestion. Intoxicated individuals display profound flaccid hypotonia, mydriasis or miosis with preserved pupillary light reflexes, and loss of protective airway reflexes.

  • Paradoxical Agitation and Combativeness: Prior to total loss of consciousness—or during the dopamine-rebound awakening phase—patients frequently exhibit violent, disorganized thrashing, shouting, and delirium.

  • Anterograde Amnesia: Complete amnesia for events occurring while under the drug’s influence, underpinning its exploitation in drug-facilitated sexual assault.

• Respiratory and Airway Emergencies (Leading Drivers of Mortality):

  • Severe Central Respiratory Depression and Apnea: Profound suppression of brainstem medullary respiratory centers mediated by $GABA_B$ activation. Patients exhibit severe Bradypnea ($<6\text{ breaths/min}$), Cheyne-Stokes respiration, or complete central apnea.

  • Fatal Pulmonary Aspiration: GBL stimulates $GABA_B$ and vagal centers, inducing sudden projectile emesis. In a comatose, supine patient with blunted pharyngeal and laryngeal protective reflexes, aspiration of acidic gastric contents leads to massive chemical pneumonitis, acute respiratory distress syndrome (ARDS), and fatal mechanical asphyxiation.

• Autonomic and Cardiovascular Effects:

  • Severe Sinus Bradycardia: Vagal tone surges can lower heart rates to $<40\text{ bpm}$.

  • Systemic Hypotension and Hypothermia: Vasodilation and central thermoregulatory depression.

• Severe, Debilitating Physical Dependence and Withdrawal Delirium:

  • Due to GBL’s rapid absorption, short half-life, and potent $GABA_B$ downregulating properties, chronic regular users develop severe neuroadaptation within days to weeks. Dependent individuals must consume GBL around the clock at tight 1- to 3-hour intervals (including waking repeatedly throughout the night to dose) to prevent the onset of withdrawal.

  • Life-Threatening GBL Withdrawal Syndrome: Abrupt cessation or missed doses precipitate a severe, rapidly escalating hyperadrenergic and hyperglutamatergic crisis within 1 to 4 hours:

    • Severe tremors, profuse diaphoresis, malignant hypertension, and severe sinus tachycardia ($>140\text{ bpm}$).

    • Extreme anxiety, insomnia, agitation, and panic.

    • Severe Visual, Auditory, and Tactile Hallucinatory Delirium (similar to severe Delirium Tremens): Frank psychosis, persecutory paranoia, extreme violent agitation, and confusion.

    • Status epilepticus, malignant hyperthermia, rhabdomyolysis, autonomic instability, and cardiovascular collapse. Unlike uncomplicated alcohol withdrawal, GBL withdrawal delirium is characteristically prolonged (persisting for 5 to 14 days) and notoriously refractory to standard doses of benzodiazepines.

• Direct Mucosal Corrosiveness: Undiluted GBL is a potent industrial solvent and chemical irritant; ingestion without substantial dilution with water produces chemical burns of the oral mucosa, oesophageal ulceration, epigastric pain, and mucosal gastritis.

6. Contraindications, Drug Interactions, and Clinical Precautions

Given its non-approved status, exceptional potency, narrow therapeutic margin, and Class B legal scheduling, the clinical management of individuals exposed to GBL requires strict emergency toxicology and addiction medicine protocols:

• Contraindications:

  • Absolute Contraindication in All Humans: Unregulated, illicit Class B substance lacking medicinal safety approval.

  • Concurrent Central Nervous System Depressants: Absolute, life-threatening hazard when combined with ethanol, opioids, benzodiazepines, or sedating psychotropics.

  • Pre-existing Respiratory Disease: Absolute hazard in asthma, chronic obstructive pulmonary disease (COPD), or sleep apnea syndromes.

  • Cardiovascular Disease: Severe hazard in baseline bradycardia, conduction abnormalities, or congestive heart failure.

  • Pregnancy and Lactation: Absolute hazard; rapidly crosses the placenta, risks severe fetal hypoxia, causes neonatal withdrawal syndrome, and distributes into breast milk.

• Drug Interactions:

  • Ethanol (Alcohol): The most common and lethal synergistic interaction. Co-ingestion of alcohol and GBL exponentially compounds respiratory depression, accelerates the onset of deep coma, paralyzes airway reflexes, and dramatically increases mortality. Alcohol competes for alcohol dehydrogenase enzymes, altering GHB clearance.

  • Opioids (e.g., Heroin, Methadone, Fentanyl, Oxycodone): Synergistic suppression of medullary respiratory drive, triggering fatal apnea and hypoxic brain injury.

  • Sedatives (e.g., Benzodiazepines, Z-drugs, Barbiturates): Additive $GABA$-mediated central depression, resulting in deep, prolonged unarousable coma.

  • Psychostimulants (e.g., Cocaine, Methamphetamine, MDMA, Cathinones): Frequently combined in “chemsex” contexts. Stimulants temporarily mask the sedative effects of GBL, encouraging users to ingest toxic cumulative doses. When the stimulant wears off, the unopposed $GABA_B$ action precipitates sudden respiratory arrest.

• Clinical Precautions and Emergency Toxicology Protocols (“Red Flags”):

  • Acute Overdose Management (The “G-Sleep” Presentation):

    • Airway Protection is Paramount: Priority must be placed on securing a patent airway and positioning the patient in the lateral recovery position immediately to prevent fatal aspiration of vomitus.

    • Ventilatory Support: Patients with severe bradypnea, hypoxemia ($SpO_2 < 90\%$), or profound coma (GCS 3) require high-flow oxygen, bag-valve-mask ventilation, and rapid sequence intubation (RSI) for mechanical ventilation.

    • Absence of a Specific Reversal Agent: Hay no licensed clinical reversal agent for GHB/GBL. Flumazenil (benzodiazepine antagonist) and naloxone (opioid antagonist) are completely ineffective against $GABA_B$/GHB receptors (naloxone should only be given if co-ingestion of opioids is suspected). Management is strictly supportive until endogenous metabolism clears the drug (typically within 2 to 6 hours).

    • Anticipation of Abrupt Dopamine-Rebound Awakening: Patients who appear deeply comatose frequently awaken suddenly within a matter of minutes, becoming disoriented, highly agitated, and combative, often attempting to extubate themselves. Emergency staff must anticipate this transition and avoid unnecessary invasive interventions if physiological parameters and airway reflexes are stable.

  • Emergency Management of Severe GBL Withdrawal:

    • GBL withdrawal is a medical emergency with high mortality if untreated. It must never be managed through abrupt cessation (“cold turkey”) in outpatient settings.

    • Hospital Admission: Patients presenting with acute GBL withdrawal require immediate admission to an acute medical unit or intensive care unit (ICU).

    • High-Dose Sedation Protocols: Because GBL withdrawal is characteristically resistant to standard benzodiazepines, treatment mandates aggressive, symptom-triggered sedation:

      • Very high doses of oral or intravenous diazepam (often requiring $>100\text{ to }200\text{ mg}$ in 24 hours under continuous cardiac and respiratory monitoring).

      • Baclofen (Specific $GABA_B$ Agonist): NHS addiction protocols increasingly employ targeted $GABA_B$ substitution utilizing licensed oral baclofen ($10\text{ mg}$ three times daily, titrating to $20\text{ to }30\text{ mg}$ TDS) in conjunction with benzodiazepines to directly substitute for missing $GABA_B$ stimulation, dramatically stabilizing autonomic delirium.

      • Refractory Delirium / ICU Escalation: Severe delirium refractory to high-dose benzodiazepines and baclofen requires ICU transfer for continuous intravenous infusions of propofol o dexmedetomidine alongside invasive mechanical ventilation.

  • Forensic and Analytical Awareness: Standard NHS hospital urine drug immunoassay screens do no detect GBL or GHB. Detection requires specialized gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS). Due to the rapid 10- to 12-hour urinary clearance window, clinicians evaluating suspected drink spiking, DFSA, or acute overdose must collect early blood and urine samples immediately and label them specifically for forensic GHB testing.

Información Adicional